Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Intuitive Surgical Inc. pages available for free this week:
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Common Stock Valuation Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Price to FCFE (P/FCFE)
- Dividend Discount Model (DDM)
- Operating Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Price to Operating Profit (P/OP) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Intuitive Surgical Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Short-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
The financial data exhibits several notable trends over the five-year period. There is a general decline in the efficiency of inventory management as indicated by the decreasing inventory turnover ratio from 2.49 in 2020 to 1.83 in 2024. Correspondingly, the average inventory processing period lengthens significantly, increasing from 147 days to 200 days, suggesting slower inventory movement and potential buildup of stock.
Receivables turnover shows some fluctuation but remains relatively stable around the mid-range values of approximately 6.6 to 7.3. The average receivable collection period also mirrors this stability, ranging narrowly between 50 and 58 days, which indicates consistent effectiveness in collecting receivables despite minor variations year over year.
Payables turnover decreases from 18.35 in 2020 to a low of 12.69 in 2023 before increasing slightly to 14.05 in 2024. This trend is reflected in the average payables payment period which extends notably from 20 days in 2020 to 29 days in 2023, then recedes slightly to 26 days. This pattern could imply a strategic extension of payment terms with suppliers during the middle years, followed by a modest reversion.
Working capital turnover improves overall with an increase from 0.77 in 2020 to 1.56 in 2024, indicating more efficient use of working capital to generate sales. Despite the slowdown in inventory turnover, this improvement suggests gains in other areas of working capital management or revenue growth outpacing the capital base.
The operating cycle shows a consistent increase from 201 days in 2020 to 254 days in 2024, highlighting an elongation in the combined duration of inventory holding and receivables collection. This is mostly driven by the increase in the inventory processing period, partially offset by steady receivables collection times.
The cash conversion cycle rises steadily from 181 days in 2020 to 228 days in 2024, illustrating a lengthening duration between cash outflows to suppliers and cash inflows from customers. This upward trend largely corresponds with the increase in inventory days and operating cycle, as well as the moderate extension of payables payment period, which tries to mitigate cash outflow timing but not sufficiently to prevent the overall increase.
In summary, the data points to challenges in inventory management and longer cash conversion processes in recent years, although there is evidence of improved working capital turnover. Receivables collection remains stable, while payment terms to suppliers appear to have been stretched before contracting slightly in the latest year. These dynamics suggest an overall trend of reduced operational efficiency in managing stock and cash flows, which could impact liquidity and require strategic attention.
Turnover Ratios
Average No. Days
Inventory Turnover
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Cost of revenue | ||||||
Inventory | ||||||
Short-term Activity Ratio | ||||||
Inventory turnover1 | ||||||
Benchmarks | ||||||
Inventory Turnover, Competitors2 | ||||||
Abbott Laboratories | ||||||
CVS Health Corp. | ||||||
Medtronic PLC | ||||||
Inventory Turnover, Sector | ||||||
Health Care Equipment & Services | ||||||
Inventory Turnover, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Inventory turnover = Cost of revenue ÷ Inventory
= ÷ =
2 Click competitor name to see calculations.
- Cost of Revenue
- The cost of revenue has exhibited a consistent upward trend throughout the five-year period. Starting from $1,497,200 thousand at the end of 2020, it increased steadily each year, reaching $2,717,900 thousand by the end of 2024. This represents a significant growth in costs, indicating either increased production volumes, higher input prices, or a combination of both.
- Inventory
- Inventory levels have also shown a consistent increase from $601,500 thousand in 2020 to $1,487,200 thousand in 2024. The growth in inventory is notable especially in the years 2022 to 2024, reflecting a possible build-up of stock. This may suggest preparation for anticipated demand increases or a slowdown in inventory turnover.
- Inventory Turnover Ratio
- The inventory turnover ratio, which measures how many times inventory is sold and replaced over a period, has declined over the same period. It started at 2.49 in 2020, peaked slightly at 2.98 in 2021, and then trended downward to 1.83 by 2024. This decline indicates that inventory is moving more slowly relative to previous years, potentially signaling decreasing efficiency in inventory management or changes in sales velocity.
- Summary
- The company has experienced substantial increases in both cost of revenue and inventory. However, the declining inventory turnover ratio suggests that the pace at which inventory is converted into sales has slowed down. This combination may point to increasing operational costs and potential challenges in inventory management. It would be advisable to further investigate the underlying causes, such as demand fluctuations or supply chain issues, to optimize inventory levels and control costs effectively.
Receivables Turnover
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Revenue | ||||||
Accounts receivable, net of allowances | ||||||
Short-term Activity Ratio | ||||||
Receivables turnover1 | ||||||
Benchmarks | ||||||
Receivables Turnover, Competitors2 | ||||||
Abbott Laboratories | ||||||
CVS Health Corp. | ||||||
Elevance Health Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. | ||||||
Receivables Turnover, Sector | ||||||
Health Care Equipment & Services | ||||||
Receivables Turnover, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Receivables turnover = Revenue ÷ Accounts receivable, net of allowances
= ÷ =
2 Click competitor name to see calculations.
- Revenue
- The revenue exhibited a consistent upward trend throughout the five-year period. Starting at approximately $4.36 billion in 2020, revenue increased to around $5.71 billion in 2021, then continued to grow to $6.22 billion in 2022, $7.12 billion in 2023, and reached $8.35 billion by the end of 2024. This steady growth reflects a strong and sustained expansion in the company's sales or service activities over the observed period.
- Accounts Receivable, Net of Allowances
- The net accounts receivable balance also showed a rising trend over the years under review. The balance increased from $645.5 million in 2020 to $782.7 million in 2021, then to $942.1 million in 2022, $1.13 billion in 2023, and $1.23 billion in 2024. This consistent increase in receivables is in line with the growing revenue, indicating an expansion in credit sales or customer balances outstanding.
- Receivables Turnover
- Receivables turnover demonstrated some variability within the period. It increased from 6.75 in 2020 to 7.3 in 2021, indicating improved efficiency in collecting receivables. However, this ratio decreased to 6.6 in 2022 and further to 6.3 in 2023, suggesting a slight decline in collection efficiency. By 2024, the ratio improved again to 6.82, although it remained slightly below the 2021 peak. Overall, while the company has generally maintained a relatively stable receivables turnover, the fluctuations may reflect changes in credit policy, customer payment behavior, or collection efforts.
Payables Turnover
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Cost of revenue | ||||||
Accounts payable | ||||||
Short-term Activity Ratio | ||||||
Payables turnover1 | ||||||
Benchmarks | ||||||
Payables Turnover, Competitors2 | ||||||
Abbott Laboratories | ||||||
CVS Health Corp. | ||||||
Elevance Health Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. | ||||||
Payables Turnover, Sector | ||||||
Health Care Equipment & Services | ||||||
Payables Turnover, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Payables turnover = Cost of revenue ÷ Accounts payable
= ÷ =
2 Click competitor name to see calculations.
- Cost of Revenue
- The cost of revenue has shown a consistent upward trend over the five-year period. Starting at $1,497,200 thousand in 2020, it increased to $2,717,900 thousand by 2024, indicating substantial growth in expenses related to producing goods or services. This steady rise suggests either an expansion of operations, increased production costs, or a combination of both factors.
- Accounts Payable
- Accounts payable also increased during the period, rising from $81,600 thousand in 2020 to $193,400 thousand in 2024. The growth, while significant, is less steep compared to the cost of revenue, which may infer a gradual increase in the company’s obligations to its suppliers or vendors.
- Payables Turnover Ratio
- The payables turnover ratio exhibited a declining trend from 18.35 in 2020 to a low of 12.69 in 2023, before a slight recovery to 14.05 in 2024. This decreasing ratio implies that the company took longer to pay its suppliers over the years, reflecting a lengthening of the accounts payable period. The minor increase in the final year may suggest a modest improvement in payment efficiency or changes in supplier terms.
Working Capital Turnover
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Current assets | ||||||
Less: Current liabilities | ||||||
Working capital | ||||||
Revenue | ||||||
Short-term Activity Ratio | ||||||
Working capital turnover1 | ||||||
Benchmarks | ||||||
Working Capital Turnover, Competitors2 | ||||||
Abbott Laboratories | ||||||
CVS Health Corp. | ||||||
Elevance Health Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. | ||||||
Working Capital Turnover, Sector | ||||||
Health Care Equipment & Services | ||||||
Working Capital Turnover, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Working capital turnover = Revenue ÷ Working capital
= ÷ =
2 Click competitor name to see calculations.
The financial data over the five-year period indicates several notable trends and developments.
- Working Capital
- The working capital figures show fluctuations throughout the period. Starting at approximately 5,660,700 US$ thousand in 2020, it declined to 4,695,100 in 2021 and remained relatively stable in 2022 at 4,830,900. It then increased significantly in 2023 to 6,229,300 before decreasing again in 2024 to 5,365,700. This pattern suggests variations in the company's short-term asset management and liquidity position across the years, with a peak in 2023.
- Revenue
- Revenue demonstrates a consistent upward progression across all years analyzed. Beginning at 4,358,400 US$ thousand in 2020, revenue increased steadily each year to reach 8,352,100 by the end of 2024. This reflects strong top-line growth averaging substantial annual increases, evidencing expanding business operations or market penetration.
- Working Capital Turnover Ratio
- The working capital turnover ratio, which measures how efficiently working capital is used to generate revenue, exhibits a general increasing trend with some fluctuations. It started below 1 at 0.77 in 2020, rose sharply to 1.22 in 2021, and slightly increased to 1.29 in 2022. There was a dip in 2023 to 1.14, followed by a significant rise to 1.56 in 2024. These changes indicate improving efficiency in utilizing working capital to generate sales overall, despite a temporary decline in 2023.
In summary, while working capital levels have exhibited variability, revenue growth has been robust and consistent. The improvement in the working capital turnover ratio over the period underscores enhanced operational efficiency in generating revenue from available working capital, particularly notable in the later years. The dip in working capital turnover in 2023 alongside the highest working capital level suggests a temporary less efficient capital utilization that recovered by 2024.
Average Inventory Processing Period
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data | ||||||
Inventory turnover | ||||||
Short-term Activity Ratio (no. days) | ||||||
Average inventory processing period1 | ||||||
Benchmarks (no. days) | ||||||
Average Inventory Processing Period, Competitors2 | ||||||
Abbott Laboratories | ||||||
CVS Health Corp. | ||||||
Medtronic PLC | ||||||
Average Inventory Processing Period, Sector | ||||||
Health Care Equipment & Services | ||||||
Average Inventory Processing Period, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =
2 Click competitor name to see calculations.
- Inventory Turnover
- The inventory turnover ratio exhibits a declining trend over the analyzed five-year period. Starting at 2.49 in 2020, it increased slightly in 2021 to 2.98 but then continuously decreased, reaching 2.27 in 2022, followed by further declines to 1.96 in 2023 and 1.83 in 2024. This reduction indicates a slower rate of inventory turnover in the latter years.
- Average Inventory Processing Period
- The average inventory processing period has shown a consistent upward trend. Beginning at 147 days in 2020, it shortened to 122 days in 2021 but then increased significantly to 161 days in 2022. This upward trajectory continued with an extension to 186 days in 2023 and further to 200 days in 2024. The increasing number of days suggests that inventory remains in stock for longer durations as time progresses.
- Overall Insight
- The inverse relationship between inventory turnover and average inventory processing period is evident. While the turnover ratio declines, the inventory processing period extends, pointing to a deceleration in the company's inventory management efficiency. This trend may highlight potential issues in demand forecasting, supply chain logistics, or changes in product sales velocity that warrant further investigation.
Average Receivable Collection Period
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data | ||||||
Receivables turnover | ||||||
Short-term Activity Ratio (no. days) | ||||||
Average receivable collection period1 | ||||||
Benchmarks (no. days) | ||||||
Average Receivable Collection Period, Competitors2 | ||||||
Abbott Laboratories | ||||||
CVS Health Corp. | ||||||
Elevance Health Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. | ||||||
Average Receivable Collection Period, Sector | ||||||
Health Care Equipment & Services | ||||||
Average Receivable Collection Period, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
- Receivables Turnover
- The receivables turnover ratio exhibited some fluctuations over the analyzed period. Beginning at 6.75 in 2020, it showed an increase to 7.3 in 2021, indicating an improvement in the efficiency of collecting receivables. However, this ratio declined to 6.6 in 2022 and further to 6.3 in 2023, suggesting a weakening in collection efficiency during these years. By 2024, the ratio increased again to 6.82, signaling a partial recovery in receivables management efficiency.
- Average Receivable Collection Period
- This metric, representing the average days taken to collect receivables, moved inversely to the turnover ratio. Starting from 54 days in 2020, it decreased to 50 days in 2021, reflecting faster collection cycles aligned with the higher turnover. However, it then extended to 55 days in 2022 and 58 days in 2023, consistent with the decrease in turnover, indicating slower collection processes in these years. In 2024, the period shortened to 54 days, aligning with the improvement observed in the receivables turnover.
- Overall Trend and Insights
- The combined trends indicate that the company experienced an improvement in receivables management efficiency in 2021, followed by a period of deterioration in 2022 and 2023. The rebound in 2024 suggests a corrective response to prior inefficiencies. These fluctuations could imply changes in credit policies, customer payment behavior, or collection efforts over time. Continuous monitoring is advisable to ensure stabilization and potential improvement in these metrics.
Operating Cycle
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data | ||||||
Average inventory processing period | ||||||
Average receivable collection period | ||||||
Short-term Activity Ratio | ||||||
Operating cycle1 | ||||||
Benchmarks | ||||||
Operating Cycle, Competitors2 | ||||||
Abbott Laboratories | ||||||
CVS Health Corp. | ||||||
Medtronic PLC | ||||||
Operating Cycle, Sector | ||||||
Health Care Equipment & Services | ||||||
Operating Cycle, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =
2 Click competitor name to see calculations.
- Average Inventory Processing Period
- The average inventory processing period exhibits a fluctuating but overall increasing trend over the five-year span. Beginning at 147 days in 2020, it decreased to 122 days in 2021, indicating improved inventory turnover during that year. However, it subsequently rose significantly to 161 days in 2022 and continued increasing to 186 days in 2023, reaching 200 days in 2024. This upward trend implies that inventory stays longer in the system, potentially pointing to slower inventory movement or increased inventory holdings.
- Average Receivable Collection Period
- The average receivable collection period shows minor fluctuations but remains relatively stable across the observed years. It started at 54 days in 2020, improved to 50 days in 2021, suggesting faster collections in that year. Thereafter, it lengthened slightly to 55 days in 2022 and peaked at 58 days in 2023 before reducing again to 54 days in 2024. This suggests that the company’s efficiency in collecting receivables remains consistent overall, without significant deterioration or improvement.
- Operating Cycle
- The operating cycle exhibits a general upward trend over the period. It decreased from 201 days in 2020 to 172 days in 2021, coinciding with improvements in both inventory processing and receivables collection periods during that year. Following this, the operating cycle increased substantially to 216 days in 2022, then to 244 days in 2023, and further to 254 days in 2024. This lengthening indicates that the total time taken from acquiring inventory to collecting cash has extended, which may impact liquidity and working capital management adversely.
Average Payables Payment Period
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data | ||||||
Payables turnover | ||||||
Short-term Activity Ratio (no. days) | ||||||
Average payables payment period1 | ||||||
Benchmarks (no. days) | ||||||
Average Payables Payment Period, Competitors2 | ||||||
Abbott Laboratories | ||||||
CVS Health Corp. | ||||||
Elevance Health Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. | ||||||
Average Payables Payment Period, Sector | ||||||
Health Care Equipment & Services | ||||||
Average Payables Payment Period, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The financial data reveals a discernible trend in the payables turnover ratio and the average payables payment period over the five-year span from 2020 to 2024.
- Payables Turnover
- The payables turnover ratio demonstrates a general downward trajectory from 18.35 in 2020 to a low of 12.69 in 2023, followed by a slight increase to 14.05 in 2024. This pattern suggests that the company’s efficiency in settling payables decreased over the initial four years but experienced a modest improvement in the most recent year.
- Average Payables Payment Period
- The average payables payment period, expressed in number of days, portrays an increasing trend from 20 days in 2020 to 29 days by 2023, before declining to 26 days in 2024. The elongation of the payment period up to 2023 aligns with the declining payables turnover ratio, reflecting a slower payment cycle. The subsequent reduction in days in 2024 indicates a partial reversal towards quicker payments.
The inverse relationship between these two metrics is consistent with typical financial behavior, where a lower turnover corresponds to a longer payment period. The extension in payment days could signify deliberate strategic management of working capital, possibly to optimize cash flow. However, the improvement in 2024 may indicate an adjustment towards balancing payment efficiency and supplier relations.
Cash Conversion Cycle
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data | ||||||
Average inventory processing period | ||||||
Average receivable collection period | ||||||
Average payables payment period | ||||||
Short-term Activity Ratio | ||||||
Cash conversion cycle1 | ||||||
Benchmarks | ||||||
Cash Conversion Cycle, Competitors2 | ||||||
Abbott Laboratories | ||||||
CVS Health Corp. | ||||||
Medtronic PLC | ||||||
Cash Conversion Cycle, Sector | ||||||
Health Care Equipment & Services | ||||||
Cash Conversion Cycle, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + – =
2 Click competitor name to see calculations.
- Average Inventory Processing Period
- The average inventory processing period shows a general upward trend over the analyzed years. Starting at 147 days in 2020, it decreased to 122 days in 2021, indicating improved inventory turnover during that period. However, from 2021 onwards, the period increased steadily to 161 days in 2022, 186 days in 2023, and 200 days in 2024, suggesting that inventory is being held for progressively longer durations recently.
- Average Receivable Collection Period
- The average receivable collection period exhibits a relatively stable pattern with minor fluctuations. It started at 54 days in 2020, improved slightly to 50 days in 2021, then increased again to 55 days in 2022 and 58 days in 2023, before returning to 54 days in 2024. Overall, the company’s efficiency in collecting receivables has been consistent without significant deterioration or improvement.
- Average Payables Payment Period
- The average payables payment period shows a gradual increase from 20 days in 2020 to 25 days in 2021. The period then slightly increased to 26 days in 2022, peaked at 29 days in 2023, and decreased back to 26 days in 2024. This trend suggests a tendency to extend payment terms to suppliers over this timeframe, with a small reversal in the final year.
- Cash Conversion Cycle
- The cash conversion cycle, which measures the number of days between outlay of cash and collection of cash inflows, shows significant variation. It declined substantially from 181 days in 2020 to 147 days in 2021, reflecting improved liquidity management during that year. Subsequently, it increased notably to 190 days in 2022, 215 days in 2023, and 228 days in 2024. The upward trend in recent years indicates an elongation of the cash conversion cycle, likely influenced by longer inventory processing and receivables collection periods, partially offset by a slightly extended payables period.